Despite recent setbacks, hedge-fund manager Kyle Bass says he’ll keep trying to invalidate what he calls weak pharmaceutical patents.
WSJ.com: Health, Wall Street Journal: Business: Health
Thu, 09/03/2015 - 3:56pm
Despite recent setbacks, hedge-fund manager Kyle Bass says he’ll keep trying to invalidate what he calls weak pharmaceutical patents.